The Retinal Vein Occlusion Therapeutics Market is expected to Witness Significant Growth Due to the Launch of Many First-in-Class Products
Significant Growth Due to the Launch of Many First-in-Class Products
GlobalData valued the Retinal Vein Occlusion (RVO) therapeutics market in 2010 at $496m, indicating a growth rate of 29.2% between 2005 and 2010. Until the market entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics market was growing at a lower rate. After the entry of Lucentis, the market registered a growth rate of 40.1% between 2006 and 2007. Up until now, Lucentis and Ozurdex have
been the only approved drugs for the treatment of RVO. The late-stage clinical development pipeline consists of 50% first-in-class and 50% me-too drugs that are effective and safe for RVO patients. Once these drugs enter the market, the market will grow further at a significant rate. Therefore, GlobalData estimates that the RVO therapeutics market in 2017 will be $1.4 billion, indicating a Compound Annual Growth Rate (CAGR) of 16% between 2010 and 2017.
The Current Competition in the Retinal Vein Occlusion Therapeutics Market is Weak
GlobalData found that the current competition in the RVO therapeutics market is weak, with only two approved drugs, Lucentis and Ozurdex (dexamethasone). Both these drugs are indicated for the treatment of macular edema following RVO. The annual cost of Lucentis runs to around $14,040 and that of Ozurdex amounts to about $6,216. Many RVO patients who cannot afford such high costs refrain from using the drug and consequently competition in the RVO therapeutics market
has become even weaker. to Witness
The Retinal Vein Occlusion Pipeline is Moderate with Few New First-in-class
Drugs in Late-stage Clinical Development
GlobalData found that the RVO pipeline is moderate, with approximately 15 molecules in the various stages of development. The majority of these molecules are me-too molecules that show mechanisms of action similar to the already existing drugs in the market. The late-stage pipeline comprises of few first-inclass
molecules, such as Lipitor (atrovastatin calcium), and Niacin (nicotinic acid). The first-in-class molecules are primarily 3-hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase inhibitors, glucocorticoid agonists, cytokine inhibitors and kallikrein inhibitors.
High Unmet Needs Exist in the Retinal Vein Occlusion Therapeutics Market in Terms of Efficacy and Safety
GlobalData found that the RVO market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with RVO are between
For further details, please click or add the below link to your browser:
45 and 85 years of age. Lucentis and Ozurdex are the only available US Food and Drug Association (FDA) approved drugs for RVO.
Therefore, the unmet need in the RVO therapeutics market was valued at 49% or $243.0m. This is expected to decrease significantly between 2010 and 2017 due to the expected launch of many first-inclass and me-too drugs.
GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global RVO market. The report identifies the key trends shaping and driving the global RVO market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global RVO sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Visit our report store: http://www.globaldata.com